My article on cyclooxygenase-2 NSAIDs 1 represents data from randomized controlled trials
and my own personal interpretation of those data. I am the managing director of the …

The new class of anti-inflammatory drugs, the COX-2 inhibitors, have been commercially
successful to the point of market dominance within a short time of their launch. They attract a …

Critical Appraisal reviews important articles in the literature relevant to family physicians.
Reviews are by family physicians, not experts on the topics. They assess not only the …

The publication in Fall 2000 of the CLASS and VIGOR trials in JAMA and the New England
Journal of Medicine (respectively) provided strong evidence for the cyclooxygenase (COX)-2 …

Reports on the urge of the US Food and Drug Administration (FDA) need for availability of
cyclooxygenase type 2 (COX-2) in the market despite its evidence on the risk of increased …

The formulation of aspirin from salicylate by Felix Hoffman in 1897 represents an early
example of translating a clinical need to laboratory pharmacology, and consequently …

WITH QUESTIONS REMAINING about the safety of nonsteroidal anti-inflammatory drugs
(NSAIDs), a Food and Drug Administration (FDA) advisory panel recommended that the …

In today's Lancet, Christopher Cannon and colleagues report on the primary and key
secondary safety analyses from the MEDAL (Multinational Etoricoxib and Diclofenac Arthritis …

The recent withdrawal of rofecoxib (Vioxx) from the worldwide market has focused intense
public scrutiny on drug safety. Although the US Food and Drug Administration monitors drug …

Regulators require less evidence to take action on drug safety concerns than would be
required to grant drug efficacy claims. Such an asymmetrical view of risk points to the need …